Advances in tau immunotherapy

Julia Gerson, Rakez Kayed

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recently tau protein has emerged as a viable therapeutic target for Alzheimer’s disease (AD) and multiple other neurodegenerative disorders known as tauopathies. Neurofibrillary tangles have long been known to be hallmarks of these disorders and to spread stereotypically through the brain. Further study into the toxicity of the protein has led many to conclude that these large fibrillar aggregates are likely not the most toxic state of tau, nor the form responsible for the spread of pathology through the brain. Rather the origin of early toxicity is likely the smaller aggregate, the oligomer. One of the most encouraging routes in which scientists can target these toxic conformations is by immunotherapy. Initial studies on immunotherapeutic approaches for AD focused on active vaccination with the Aβ protein, however this strategy proved to have some concerns with both safety and efficacy. While Aβ is an early mediator of toxicity in AD, tau lies downstream and without targeting it as well, toxicity will still remain. Moreover, active vaccination of both Aβ and later of tau led to inflammation and encephalitis. Therefore, a focus on passive immunotherapy with tau-specific antibodies began. Though initial studies were based on hyperphosphorylated tau epitopes, the most promising results recently have targeted forms of tau that occur early in disease and lead to decreased levels of soluble, oligomeric tau. This chapter will outline the latest advances in the field of tau immunotherapy and the aspects of the strategy that are not yet fully understood.

Original languageEnglish (US)
Title of host publicationResearch Progress in Alzheimer’s Disease and Dementia. Volume 6
PublisherNova Science Publishers, Inc.
Pages99-114
Number of pages16
ISBN (Electronic)9781634852067
ISBN (Print)9781634851725
StatePublished - Jan 1 2016

Fingerprint

Toxicity
Protein
Alzheimer's disease
Vaccination
Antibody
Safety
Efficacy
Mediator
Targeting
Pathology

ASJC Scopus subject areas

  • Economics, Econometrics and Finance(all)
  • Business, Management and Accounting(all)

Cite this

Gerson, J., & Kayed, R. (2016). Advances in tau immunotherapy. In Research Progress in Alzheimer’s Disease and Dementia. Volume 6 (pp. 99-114). Nova Science Publishers, Inc..

Advances in tau immunotherapy. / Gerson, Julia; Kayed, Rakez.

Research Progress in Alzheimer’s Disease and Dementia. Volume 6. Nova Science Publishers, Inc., 2016. p. 99-114.

Research output: Chapter in Book/Report/Conference proceedingChapter

Gerson, J & Kayed, R 2016, Advances in tau immunotherapy. in Research Progress in Alzheimer’s Disease and Dementia. Volume 6. Nova Science Publishers, Inc., pp. 99-114.
Gerson J, Kayed R. Advances in tau immunotherapy. In Research Progress in Alzheimer’s Disease and Dementia. Volume 6. Nova Science Publishers, Inc. 2016. p. 99-114
Gerson, Julia ; Kayed, Rakez. / Advances in tau immunotherapy. Research Progress in Alzheimer’s Disease and Dementia. Volume 6. Nova Science Publishers, Inc., 2016. pp. 99-114
@inbook{62a4c192a588460cbcc5a89fac0604d4,
title = "Advances in tau immunotherapy",
abstract = "Recently tau protein has emerged as a viable therapeutic target for Alzheimer’s disease (AD) and multiple other neurodegenerative disorders known as tauopathies. Neurofibrillary tangles have long been known to be hallmarks of these disorders and to spread stereotypically through the brain. Further study into the toxicity of the protein has led many to conclude that these large fibrillar aggregates are likely not the most toxic state of tau, nor the form responsible for the spread of pathology through the brain. Rather the origin of early toxicity is likely the smaller aggregate, the oligomer. One of the most encouraging routes in which scientists can target these toxic conformations is by immunotherapy. Initial studies on immunotherapeutic approaches for AD focused on active vaccination with the Aβ protein, however this strategy proved to have some concerns with both safety and efficacy. While Aβ is an early mediator of toxicity in AD, tau lies downstream and without targeting it as well, toxicity will still remain. Moreover, active vaccination of both Aβ and later of tau led to inflammation and encephalitis. Therefore, a focus on passive immunotherapy with tau-specific antibodies began. Though initial studies were based on hyperphosphorylated tau epitopes, the most promising results recently have targeted forms of tau that occur early in disease and lead to decreased levels of soluble, oligomeric tau. This chapter will outline the latest advances in the field of tau immunotherapy and the aspects of the strategy that are not yet fully understood.",
author = "Julia Gerson and Rakez Kayed",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781634851725",
pages = "99--114",
booktitle = "Research Progress in Alzheimer’s Disease and Dementia. Volume 6",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Advances in tau immunotherapy

AU - Gerson, Julia

AU - Kayed, Rakez

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Recently tau protein has emerged as a viable therapeutic target for Alzheimer’s disease (AD) and multiple other neurodegenerative disorders known as tauopathies. Neurofibrillary tangles have long been known to be hallmarks of these disorders and to spread stereotypically through the brain. Further study into the toxicity of the protein has led many to conclude that these large fibrillar aggregates are likely not the most toxic state of tau, nor the form responsible for the spread of pathology through the brain. Rather the origin of early toxicity is likely the smaller aggregate, the oligomer. One of the most encouraging routes in which scientists can target these toxic conformations is by immunotherapy. Initial studies on immunotherapeutic approaches for AD focused on active vaccination with the Aβ protein, however this strategy proved to have some concerns with both safety and efficacy. While Aβ is an early mediator of toxicity in AD, tau lies downstream and without targeting it as well, toxicity will still remain. Moreover, active vaccination of both Aβ and later of tau led to inflammation and encephalitis. Therefore, a focus on passive immunotherapy with tau-specific antibodies began. Though initial studies were based on hyperphosphorylated tau epitopes, the most promising results recently have targeted forms of tau that occur early in disease and lead to decreased levels of soluble, oligomeric tau. This chapter will outline the latest advances in the field of tau immunotherapy and the aspects of the strategy that are not yet fully understood.

AB - Recently tau protein has emerged as a viable therapeutic target for Alzheimer’s disease (AD) and multiple other neurodegenerative disorders known as tauopathies. Neurofibrillary tangles have long been known to be hallmarks of these disorders and to spread stereotypically through the brain. Further study into the toxicity of the protein has led many to conclude that these large fibrillar aggregates are likely not the most toxic state of tau, nor the form responsible for the spread of pathology through the brain. Rather the origin of early toxicity is likely the smaller aggregate, the oligomer. One of the most encouraging routes in which scientists can target these toxic conformations is by immunotherapy. Initial studies on immunotherapeutic approaches for AD focused on active vaccination with the Aβ protein, however this strategy proved to have some concerns with both safety and efficacy. While Aβ is an early mediator of toxicity in AD, tau lies downstream and without targeting it as well, toxicity will still remain. Moreover, active vaccination of both Aβ and later of tau led to inflammation and encephalitis. Therefore, a focus on passive immunotherapy with tau-specific antibodies began. Though initial studies were based on hyperphosphorylated tau epitopes, the most promising results recently have targeted forms of tau that occur early in disease and lead to decreased levels of soluble, oligomeric tau. This chapter will outline the latest advances in the field of tau immunotherapy and the aspects of the strategy that are not yet fully understood.

UR - http://www.scopus.com/inward/record.url?scp=85021954319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021954319&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85021954319

SN - 9781634851725

SP - 99

EP - 114

BT - Research Progress in Alzheimer’s Disease and Dementia. Volume 6

PB - Nova Science Publishers, Inc.

ER -